RDY - DR REDDYS LABORATORIES LTD
Close
15.86
-0.110 -0.694%
Share volume: 33,851
Last Updated: Fri 27 Dec 2024 05:29:31 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.45%
PREVIOUS CLOSE
CHG
CHG%
$15.97
-0.11
-0.69%
Fundamental analysis
47%
Profitability
46%
Dept financing
16%
Liquidity
53%
Performance
55%
Performance
5 Days
1.16%
1 Month
10.82%
3 Months
-80.40%
6 Months
-78.25%
1 Year
-76.71%
2 Year
-69.38%
Key data
Stock price
$15.86
DAY RANGE
$15.91 - $16.04
52 WEEK RANGE
$14.14 - $84.46
52 WEEK CHANGE
-$77.54
DIVIDEND
$0.4792
EX-DIVIDEND DATE
07/30/2024
NEXT EARNINGS DATE
10/24/2024
Company detail
CEO: Erez Israeli
Region: US
Website: drreddys.com
Employees: 24,800
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: drreddys.com
Employees: 24,800
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others segments. Its therapeutic categories include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Recent news